Illumina -- 5.9/10 -- $127.31

HOLD / WATCHLIST

NASDAQ: ILMN | Genomic sequencing leader with ~60-66% global NGS instrument share. Near 52-week highs at $127, up 62% YoY. Trailing P/E 23.4x on $4.34B revenue. Post-GRAIL spinoff turnaround under new CEO Jacob Thaysen gaining traction -- clinical consumables grew 20% ex-China in Q4 2025, FCF recovered to $931M, and non-GAAP EPS grew 16%. However, reported revenue declined three consecutive years, instrument franchise is shrinking, and the turnaround is increasingly priced in with the stock above consensus targets. Next earnings May 7, 2026.

FY2025 Revenue

$4.34B

-0.7% YoY reported | +2% ex-China | Q4 +5%

FY2025 Free Cash Flow

$931M

+34% YoY | exceeded pre-GRAIL peak

Trailing P/E

23.4x

Fwd P/E 24.9x | in-line with life sci peers

Composite Score

5.9 / 10

HOLD - Borderline, turnaround not yet proven

Quality gate results

Oligopoly / Dominant Position

PASS

~60-66% of global NGS instrument installations, down from ~80% at peak but still dominant. Clinical switching costs (validation, IVD approvals, DRAGEN informatics) create a 3-5 year moat. However, Element Biosciences, Ultima Genomics, and Roche SBX are credible challengers -- the oligopoly is real but eroding from near-monopoly toward contested leadership.

Positive and Growing FCF

PASS

FCF recovered from a $106M trough in 2022 to $931M in 2025 (+34% YoY), exceeding the pre-GRAIL level of $891M. Cash conversion is strong, funding $740M of share repurchases in 2025. Quarterly FCF was consistently positive ($200-267M per quarter in 2025). This is the strongest dimension of the turnaround.

Management 3+ Year Track Record

PASS

CEO Jacob Thaysen (since Nov 2023) brings Danaher-style operational discipline. 10 of 11 promises met or on track, 1 exceeded. Beat-and-raise guidance pattern throughout 2025. Board refreshed with Scott Gottlieb (former FDA Commissioner) and Keith Meister (Corvex activist). CFO Ankur Dhingra (ex-Danaher) reinforces cost focus. Short tenure but strong early execution.

Gate result: All three gates PASS. Illumina retains dominant NGS market share (~60-66%), FCF has staged a genuine recovery to $931M (exceeding pre-GRAIL levels), and the Thaysen management team has delivered on nearly every promise made since taking over. The concern is not the gates themselves but the eroding oligopoly trajectory and the fact that the turnaround is increasingly reflected in the stock price at $127 (above consensus targets).

Score breakdown

/ 10

Financial Trends Weight: 25%

Revenue declined three consecutive years (2023-2025) on a reported basis, only inflecting positive in late 2025. Q4 revenue grew +5% YoY, and ex-China growth was +7% in Q4 -- a clear inflection. Non-GAAP EPS grew 16% to $4.84, with Q4 accelerating to +42% YoY. FCF recovered to $931M (+34%). Gross margin at 66.1% is improving but remains ~360 bps below 2021 peaks. Instrument revenue still contracting (-3.9%). 2026 guided at 4-6% revenue growth and $5.00-$5.20 EPS. Turnaround is directionally correct but not yet proven.

/ 10

Thematic Exposure Weight: 25%

Genomic sequencing sits at the center of precision medicine -- one of the strongest secular themes in healthcare. Clinical adoption is inflecting: 20% ex-China clinical consumable growth in Q4 2025, driven by MRD, whole genome sequencing, and expanded reimbursement. Population genomics programs expanding globally (UK Biobank, All of Us). TAM estimated at $100B+ in clinical alone. However, the oligopoly is eroding: Element Biosciences, Ultima Genomics, and Roche SBX are credible challengers, and ILMN share has declined from ~80% to ~60-66%. The theme is powerful; monetization is no longer uncontested.

/ 10

Management Quality Weight: 20%

CEO Jacob Thaysen (ex-Danaher) has delivered a Danaher-style operational turnaround since Nov 2023. Promise tracking: 10/11 met or on track, 1 exceeded. Beat-and-raise guidance pattern through all of 2025 -- original EPS guide of $4.20-$4.30 raised to $4.65-$4.75, delivered $4.84. Operating margin expanded 180 bps despite 200 bps tariff drag. Board refreshed with Scott Gottlieb (former FDA Commissioner) and Keith Meister (Corvex). CFO Ankur Dhingra brings additional Danaher cost discipline. Short tenure is the main caveat.

/ 10

Investor Sentiment Weight: 15%

Stock up 62% YoY and trading near 52-week highs at $127, above the consensus analyst target of ~$124. The turnaround narrative is well-established and increasingly priced in. Consensus rating is Hold (not a crowded long, but not unloved either). Post-Q4 earnings selloff of 10-13% despite beat-and-raise suggests buy-side expectations had gotten ahead of fundamentals. Short interest at 5.4% is moderately elevated. Emerging competitive threats from Element/Ultima/Roche not yet fully priced. Limited margin of safety at current levels -- the easy turnaround money has been made.

/ 10

Concerns, Catalysts & Risks Weight: 15%

Balanced risk/reward. Key catalysts: clinical consumable acceleration (guided double-digit to mid-teens 2026), margin expansion toward 26% by 2027, NIH funding stabilization, population genomics ramp, and multiomics product launches. Key risks: NIH budget cuts weighing on research spending (mid-to-high single-digit consumable declines), China export restrictions (<5% of revenue), intensifying competition from Element/Ultima/Roche, tariff headwinds on margins, and a valuation (24.9x fwd P/E) that already embeds successful turnaround. Stock above consensus targets limits margin of safety.

Dimension	Score	Weight	Weighted
Financial Trends	5	25%	1.25
Thematic Exposure	7	25%	1.75
Management Quality	7	20%	1.40
Investor Sentiment	4	15%	0.60
Concerns, Catalysts & Risks	6	15%	0.90
Composite		100%	5.9

Company overview

Illumina is the dominant provider of next-generation sequencing (NGS) instruments and consumables, commanding ~60-66% of global NGS instrument installations. The company operates a razor/blade business model: sequencing instruments (~11% of revenue) generate recurring consumable pull-through (~68% of revenue) from flow cells and reagents. Headquartered in San Diego, California, with a calendar fiscal year.

The investment case centers on a turnaround under new leadership. CEO Jacob Thaysen (ex-Danaher, since Nov 2023) and CFO Ankur Dhingra have brought operational discipline to a company that was severely mismanaged during the GRAIL acquisition era. The GRAIL divestiture (completed Sep 2024) removed a major capital drain, and the management team has delivered on virtually every promise: operating margin expanded 180 bps in FY2025, non-GAAP EPS grew 16%, FCF recovered to $931M, and the NovaSeq X transition exceeded targets. Clinical consumables -- the core growth engine -- grew 20% ex-China in Q4 2025.

The challenge is that the turnaround is increasingly priced in. The stock has rallied 62% YoY to $127, above the consensus analyst target of ~$124. Reported revenue still declined in FY2025 (-0.7%), instrument revenue is in structural decline from the NovaSeq X transition, research end markets remain weak (mid-to-high single-digit declines) due to NIH funding uncertainty, and the competitive landscape is intensifying with Element Biosciences, Ultima Genomics, and Roche all launching credible alternatives. The oligopoly moat is real but narrowing from near-monopoly toward contested leadership.

Price	$127.31	FY2025 Revenue	$4.34B (-0.7% YoY)
Market Cap	$19.48B	FY2025 Gross Margin	66.1% (recovering from 60.9% trough)
Forward P/E	24.9x	Non-GAAP EPS (FY25)	$4.84 (+16% YoY)
Trailing P/E	23.4x	FCF (FY2025)	$931M (+34% YoY)
52-Week Range	~$80 - $130	Seq. Consumables (FY25)	$2.94B (+2.3% YoY)
Beta	1.49	Next Earnings	May 7, 2026

Summary thesis

ILMN receives a composite score of 5.9/10, reflecting strong thematic positioning (7) and credible management execution (7), offset by mixed financials (5) with revenue still declining on a reported basis, crowded sentiment (4) after a 62% rally, and a balanced but watchful risk profile (6). The score sits just below the threshold for a constructive view.

Bull case (~$160-180, +25-40%): Clinical consumable acceleration continues at double-digit to mid-teens growth through 2026. Research end markets stabilize as NIH funding clarity improves. Operating margin reaches 26% target by 2027. Multiomics launches (spatial, proteomics via SomaLogic) contribute incremental growth. Population genomics programs ramp. Non-GAAP EPS reaches $6.00+ by 2027. P/E re-rates to 28-30x on sustained growth visibility.

Base case (~$130-150, +2-18%): FY2026 delivers 4-6% reported revenue growth as guided. Clinical momentum continues but research weakness persists. Operating margin expands to ~23.5% as guided. EPS of $5.00-$5.20. Competitive threats emerge but do not materially erode share in 2026. Stock trades sideways to modestly higher as turnaround execution continues but is already priced in.

Bear case (~$85-100, -20-35%): Research funding cuts deepen. Element Biosciences and Roche SBX gain meaningful traction, compressing pricing and share. Tariff headwinds persist. SomaLogic integration proves more dilutive than expected. Revenue growth disappoints vs. 4-6% guide. P/E compresses to 18-20x as growth thesis stalls. The turnaround narrative loses credibility.

Bottom line: Illumina is a high-quality franchise executing a credible turnaround, but the stock has largely priced in the recovery. The clinical sequencing theme is powerful and durable, management is delivering, and the FCF recovery is genuine. However, three years of reported revenue decline, an eroding competitive moat, crowded sentiment after a 62% rally, and a forward P/E of 24.9x leave limited margin of safety. HOLD / Watchlist, with clear upgrade triggers: (1) Q1 2026 earnings confirm revenue inflection with reported growth accelerating above 4%, (2) research end market stabilization providing upside to guidance, (3) stock pulls back to $105-110 range (20x fwd P/E) offering better entry. Any two of these three would warrant upgrading to a constructive view.

What to watch

Key catalysts and monitoring points:

Q1 2026 earnings (May 7, 2026): First full quarter with SomaLogic consolidated. Watch for clinical consumable growth trajectory (guided double-digit to mid-teens) and any signs of research stabilization. Revenue needs to show reported YoY growth to validate the inflection. Non-GAAP operating margin guided at 23.3-23.5% for the year.
NIH funding clarity: Research consumables are declining mid-to-high single digits due to grant funding uncertainty. Any stabilization in NIH budgets would provide upside to guidance and could shift the research trajectory from headwind to neutral.
Competitive landscape -- Roche SBX launch: Roche is the most credible threat to clinical sequencing dominance given its diagnostics channel and regulatory infrastructure. Track SBX commercial traction and any customer displacement reports.
Element Biosciences / Ultima Genomics: Element Vitari benchtop sequencer due late 2026 with $100 genomes. Ultima offering $80/genome for bulk WGS. Monitor academic lab adoption and pricing pressure signals.
NovaSeq X consumable pull-through: 890 installed instruments at end of Q4 2025. Watch for utilization ramp as clinical transition progresses (now >2/3 complete). Clinical pull-through is the key revenue driver.
Operating margin progression toward 26% by 2027: The margin expansion story is the most tangible part of the turnaround. Q4 2025 exit rate was 23.7%. Track quarterly progression toward the 26% target.
Multiomics contribution: Spatial transcriptomics and Constellation MAP Read expected in 2026. SomaLogic proteomics adds capability. Management expects 1-2% incremental growth from multiomics by 2027 -- watch for early traction signals.
China resolution: Less than 5% of revenue but a drag on reported growth. Any easing of export restrictions or UAL resolution would provide upside.

For the full analysis, see the Financials, Thematics, Management, and Sentiment pages.

Data sourced from Daloopa (company_id: 432) and ILMN earnings transcripts (Q3 2024 through Q4 2025).